Literature DB >> 9336022

DNA vaccines.

D L Montgomery1, J B Ulmer, J J Donnelly, M A Liu.   

Abstract

In just a few years, injection of plasmid DNA to elicit immune responses in vivo has developed from an interesting observation to a viable vaccine strategy. DNA vaccines have been shown to elicit both cellular and humoral immune responses and to be effective in a variety of preclinical bacterial, viral, and parasitic animal models. This review will discuss the current knowledge of vector design, methods of plasmid delivery, immune responses elicited by various DNA vaccines, safety issues, and production and release of plasmid as a vaccine product. The potential of this new vaccine strategy and its future prospects is summarized.

Mesh:

Substances:

Year:  1997        PMID: 9336022     DOI: 10.1016/s0163-7258(97)82003-7

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  18 in total

1.  Long-term protective immune response elicited by vaccination with an expression genomic library of Toxoplasma gondii.

Authors:  Alberto Fachado; Alexandro Rodriguez; Judith Molina; Jaline C Silvério; Ana P M P Marino; Luzia M O Pinto; Sergio O Angel; Juan F Infante; Yara Traub-Cseko; Regina R Amendoeira; Joseli Lannes-Vieira
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

2.  Development and evaluation of chitosan-coated liposomes for oral DNA vaccine: the improvement of Peyer's patch targeting using a polyplex-loaded liposomes.

Authors:  Sunee Channarong; Wanpen Chaicumpa; Nuttanan Sinchaipanid; Ampol Mitrevej
Journal:  AAPS PharmSciTech       Date:  2010-12-31       Impact factor: 3.246

3.  Protective immunity induced by a DNA vaccine-encoding Toxoplasma gondii microneme protein 11 against acute toxoplasmosis in BALB/c mice.

Authors:  Qing Tao; Rui Fang; Weichao Zhang; Yifan Wang; Jianxi Cheng; Yalin Li; Kun Fang; Muhammad Kasib Khan; Min Hu; Yanqin Zhou; Junlong Zhao
Journal:  Parasitol Res       Date:  2013-06-10       Impact factor: 2.289

4.  Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.

Authors:  M A Egan; W A Charini; M J Kuroda; J E Schmitz; P Racz; K Tenner-Racz; K Manson; M Wyand; M A Lifton; C E Nickerson; T Fu; J W Shiver; N L Letvin
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  High-efficiency gene transfer into skeletal muscle mediated by electric pulses.

Authors:  L M Mir; M F Bureau; J Gehl; R Rangara; D Rouy; J M Caillaud; P Delaere; D Branellec; B Schwartz; D Scherman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

Review 6.  DNA and RNA-based vaccines: principles, progress and prospects.

Authors:  W W Leitner; H Ying; N P Restifo
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

7.  An RNA vaccine based on recombinant Semliki Forest virus particles expressing the Cu,Zn superoxide dismutase protein of Brucella abortus induces protective immunity in BALB/c mice.

Authors:  Angel A Oñate; Gabriel Donoso; Gustavo Moraga-Cid; Hugo Folch; Sandra Céspedes; Edilia Andrews
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

8.  Immunological diversity within a family of cutinase-like proteins of Mycobacterium tuberculosis.

Authors:  Nicholas P West; Teresa M Wozniak; Jesus Valenzuela; Carl G Feng; Alan Sher; Jose M C Ribeiro; Warwick J Britton
Journal:  Vaccine       Date:  2008-05-23       Impact factor: 3.641

9.  A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes.

Authors:  Ronald L Veselenak; Mark Shlapobersky; Richard B Pyles; Qun Wei; Sean M Sullivan; Nigel Bourne
Journal:  Vaccine       Date:  2012-10-04       Impact factor: 3.641

10.  The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis.

Authors:  Alaa Bassuny Ismael; Dalila Sekkai; Christine Collin; Daniel Bout; Marie-Noëlle Mévélec
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.